Modulating inflammation and neuroprotection in multiple sclerosis

Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications

(2017) Yun Cheng et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis

(2017) Emanuele Pravatà et al.   Multiple Sclerosis Journal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

(2017) Paolo A. Muraro et al.   JAMA Neurology

Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis

(2017) Emanuele Pravatà et al.   Multiple Sclerosis Journal

Novel Agents for Relapsing Forms of Multiple Sclerosis

(2016) Rebecca Straus Farber et al.   Annual Review of Medicine

Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells

(2016) Sarah E. Fiedler et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Oxidative stress in multiple sclerosis: Central and peripheral mode of action

(2016) Kim Ohl et al.   EXPERIMENTAL NEUROLOGY

Role of regulatory b cells in neuroimmunologic disorders

(2016) Jinming Han et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study

(2016) Laure Peyro Saint Paul et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

(2016) Harold L Atkins et al.   LANCET

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

(2016) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

Therapies: Progressive steps

(2016) Elie Dolgin   NATURE

Hydroxycitric acid ameliorates inflammation and oxidative stress in mouse models of multiple sclerosis

(2016) Sanaz Afraei et al.   Neural Regeneration Research

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

(2016) Ludwig Kappos et al.   NEUROLOGY

Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse

(2016) Ye Zhang et al.   NEURON

New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis

(2016) Bożena Adamczyk et al.   Oxidative Medicine and Cellular Longevity

Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?

(2016) Maha M. Bakhuraysah et al.   Stem Cell Research & Therapy

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis

(2015) Sunny Malhotra et al.   BRAIN

Dimethyl fumarate attenuates cerebral edema formation by protecting the blood–brain barrier integrity

(2015) Reiner Kunze et al.   EXPERIMENTAL NEUROLOGY

The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity

(2015) Andrew L. Croxford et al.   IMMUNITY

The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: Interleukin-17A and interleukin-17F serum levels

(2015) Zohreh Babaloo et al.   IMMUNOLOGY LETTERS

Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study

(2015) Emmanuelle Le Page et al.   JOURNAL OF NEUROLOGY

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

(2015) J Kuhle et al.   Multiple Sclerosis Journal

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

(2015) George D. Kalliolias et al.   Nature Reviews Rheumatology

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial

(2015) Claire M. Rice et al.   Trials

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

(2015) J Kuhle et al.   Multiple Sclerosis Journal

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

(2015) Per Soelberg Sorensen et al.   Therapeutic Advances in Neurological Disorders

Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes

(2015) He Huang et al.   Redox Biology

From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development

(2014) Avraham Ben-Nun et al.   JOURNAL OF AUTOIMMUNITY

Cutting Edge: Th1 Cells Facilitate the Entry of Th17 Cells to the Central Nervous System during Experimental Autoimmune Encephalomyelitis

(2014) R. A. O'Connor et al.   JOURNAL OF IMMUNOLOGY

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

(2014) T. L. Vollmer et al.   JOURNAL OF NEUROLOGY

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

(2014) Ludwig Kappos et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

(2014) P. Browne et al.   NEUROLOGY

Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study

(2014) Katrin Strassburger-Krogias et al.   Therapeutic Advances in Neurological Disorders

SIRT1 Activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease

(2014) Reas S Khan et al.   Acta Neuropathologica Communications

MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis

(2013) Peizhong Mao et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Disease-specific molecular events in cortical multiple sclerosis lesions

(2013) Marie Therese Fischer et al.   BRAIN

Novel immunoregulatory properties of EGCG on reducing inflammation in EAE

(2013) Hong Nie   Frontiers in Bioscience-Landmark

MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies

(2013) Nicolas Molnarfi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse

(2013) Sebastian M. Fiebiger et al.   JOURNAL OF NEUROIMMUNOLOGY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

(2013) Krzysztof Selmaj et al.   LANCET NEUROLOGY

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination

(2012) Thomas Skripuletz et al.   BRAIN

Cortical lesion load associates with progression of disability in multiple sclerosis

(2012) M. Calabrese et al.   BRAIN

The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response

(2012) Lorenz C. Hundgeburth et al.   CLINICAL IMMUNOLOGY

Mitochondrial changes within axons in multiple sclerosis

(2012) Graham R. Campbell et al.   CURRENT OPINION IN NEUROLOGY

Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis

(2012) J. A. Quandt et al.   JOURNAL OF IMMUNOLOGY

Ferritin Stimulates Oligodendrocyte Genesis in the Adult Spinal Cord and Can Be Transferred from Macrophages to NG2 Cells In Vivo

(2012) D. L. Schonberg et al.   JOURNAL OF NEUROSCIENCE

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Animal models of multiple sclerosis: the good, the bad and the bottom line

(2012) Richard M Ransohoff   NATURE NEUROSCIENCE

Progressive multiple sclerosis: pathology and pathogenesis

(2012) Hans Lassmann et al.   Nature Reviews Neurology

Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned

(2012) Harold L. Atkins et al.   Neurotherapeutics

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation

(2012) Dimitrios Davalos et al.   Nature Communications

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Oxidative damage in multiple sclerosis lesions

(2011) L. Haider et al.   BRAIN

Risks and benefits of multiple sclerosis therapies: need for continual assessment?

(2011) Bernd C Kieseier et al.   CURRENT OPINION IN NEUROLOGY

The molecular basis of neurodegeneration in multiple sclerosis

(2011) Hans Lassmann et al.   FEBS LETTERS

Identification of a microglia phenotype supportive of remyelination

(2011) Marta Olah et al.   GLIA

Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice

(2011) V. Abraira et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis

(2011) Priya Chaudhary et al.   JOURNAL OF NEUROIMMUNOLOGY

EMMPRIN: A Novel Regulator of Leukocyte Transmigration into the CNS in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis

(2011) S. M. Agrawal et al.   JOURNAL OF NEUROSCIENCE

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis

(2011) Ivana Nikić et al.   NATURE MEDICINE

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Excess Circulating Alternatively Activated Myeloid (M2) Cells Accelerate ALS Progression While Inhibiting Experimental Autoimmune Encephalomyelitis

(2011) Ilan Vaknin et al.   PLoS One

Disruption of central nervous system barriers in multiple sclerosis

(2010) Jorge Ivan Alvarez et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis

(2010) Áine C. Murphy et al.   BRAIN BEHAVIOR AND IMMUNITY

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis

(2010) J. M. Fletcher et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Gadofluorine M-enhanced MRI shows involvement of circumventricular organs in neuroinflammation

(2010) Eva Wuerfel et al.   Journal of Neuroinflammation

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

(2010) Ernst-Wilhelm Radue et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

(2010) JF Lovera et al.   Multiple Sclerosis Journal

Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study

(2010) F. Sangalli et al.   NEUROLOGICAL SCIENCES

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

(2010) Fredrik Piehl et al.   NEUROLOGICAL SCIENCES

Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse

(2010) Darius Moharregh-Khiabani et al.   PLoS One

Animal models of multiple sclerosis—Potentials and limitations

(2010) Eilhard Mix et al.   PROGRESS IN NEUROBIOLOGY

Exploring the roles of CD8+ T lymphocytes in the pathogenesis of autoimmune demyelination

(2010) Trina A. Johnson et al.   Seminars in Immunopathology

Immunopathogenesis of multiple sclerosis

(2009) MichaelK Racke   Annals of Indian Academy of Neurology

Pathogenic CD8+T cells in multiple sclerosis

(2009) Manuel A. Friese et al.   ANNALS OF NEUROLOGY

Mitochondrial changes within axons in multiple sclerosis

(2009) D. J. Mahad et al.   BRAIN

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

Axonal degeneration in multiple sclerosis: The mitochondrial hypothesis

(2009) Kimmy G. Su et al.   Current Neurology and Neuroscience Reports

Tempol ameliorates murine viral encephalomyelitis by preserving the blood–brain barrier, reducing viral load, and lessening inflammation

(2009) Maria Heloisa Tsuhako et al.   FREE RADICAL BIOLOGY AND MEDICINE

Tempol protection of spinal cord mitochondria from peroxynitrite-induced oxidative damage

(2009) Yiqin Xiong et al.   FREE RADICAL RESEARCH

Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis

(2009) Pablo Kizelsztein et al.   JOURNAL OF NEUROIMMUNOLOGY

Identification of Two Distinct Macrophage Subsets with Divergent Effects Causing either Neurotoxicity or Regeneration in the Injured Mouse Spinal Cord

(2009) K. A. Kigerl et al.   JOURNAL OF NEUROSCIENCE

Knowns and unknowns in the future of multiple sclerosis treatment

(2009) Olaf Stüve   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Advanced magnetic resonance imaging metrics: Implications for multiple sclerosis clinical trials

(2009) R. Zivadinov   METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo

(2009) Mandy J McGeachy et al.   NATURE IMMUNOLOGY

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

Cortical lesions in primary progressive multiple sclerosis: A 2-year longitudinal MR study

(2009) M. Calabrese et al.   NEUROLOGY

Blockade of Glutamate Release from Microglia Attenuates Experimental Autoimmune Encephalomyelitis in Mice

(2009) Jin Shijie et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

The Absence of the Pro-antioxidant Transcription Factor Nrf2 Exacerbates Experimental Autoimmune Encephalomyelitis

(2009) Delinda A. Johnson et al.   TOXICOLOGICAL SCIENCES

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL

Complement in multiple sclerosis: its role in disease and potential as a biomarker

(2008) G. Ingram et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Antioxidant therapy in multiple sclerosis

(2008) Abbas Mirshafiey et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Neuroprotective Effects of Tempol, a Catalytic Scavenger of Peroxynitrite-Derived Free Radicals, in a Mouse Traumatic Brain Injury Model

(2008) Ying Deng-Bryant et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Regional CNS responses to IFN-γ determine lesion localization patterns during EAE pathogenesis

(2008) Jason R. Lees et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS

(2008) Richard A. Rudick et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

(2008) Gianluigi Mancardi et al.   LANCET NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Memantine induces reversible neurologic impairment in patients with MS

(2008) P. Villoslada et al.   NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice

(2008) M. C. Ghosh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Immunology of Multiple Sclerosis

(2008) Amit Bar-Or   SEMINARS IN NEUROLOGY

Th17 Cells and Autoimmune Encephalomyelitis (EAE/MS)

(2008) Toshimasa Aranami et al.   ALLERGOLOGY INTERNATIONAL

Review: Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?

(2007) R.E. Gonsette   Multiple Sclerosis Journal